Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine rich repeat containing 34 pseudogene 2 (LRRC34P2) is a processed pseudogene, meaning it is a non-protein-coding sequence in the genome derived from the retrotransposition of mRNA of the parental gene LRRC34[1]. Processed pseudogenes like LRRC34P2 typically do not code for functional proteins and are generally not considered valid therapeutic or pharmacological targets[3][1]. While some pseudogenes have gained new regulatory or RNA-based functions, there is no specific functional or disease-related evidence for LRRC34P2[1][3]. The gene is present in several primate species but not in humans under this designation[1]. Thus, LRRC34P2 is not a biologically relevant molecular target in the classical sense of receptors, enzymes, or transporters, but instead is classified as a pseudogene[4][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine rich repeat containing 34 pseudogene 2 (LRRC34P2).